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Abstract
Interest in the role of extracellular vesicles in various diseases including cancer has been increasing. Extracellular vesicles
include microvesicles, exosomes, apoptotic bodies, and argosomes, and are classified by size, content, synthesis, and
function. Currently, the best characterized are exosomes and microvesicles. Exosomes are small vesicles (40-100 nm)
involved in intercellular communication regardless of the distance between them. They are found in various biological fluids
such as plasma, serum, and breast milk, and are formed from multivesicular bodies through the inward budding of the
endosome membrane. Microvesicles are 100-1000 nm vesicles released from the cell by the outward budding of the plasma
membrane. The therapeutic potential of extracellular vesicles is very broad, with applications including a route of drug delivery
and as biomarkers for diagnosis. Extracellular vesicles extracted from stem cells may be used for treatment of many diseases
including kidney diseases. This review highlights mechanisms of synthesis and function, and the potential uses of well-
characterized extracellular vesicles, mainly exosomes, with a special focus on renal functions and diseases.
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Introduction
The importance and role of extracellular vesicles, such
as microvesicles and exosomes, are well documented in
many diseases. Several studies have analyzed the effect
of extracellular vesicles in cellular communication, but the
different populations of extracellular vesicles are often
presented in a confusing manner in the literature.
Microvesicles are larger than exosomes (100-1000 nm)
and are released into the extracellular space by outward
budding of the cell membrane. On the other hand,
exosomes are produced by a more complex inward
budding of endosomes (1). Both microvesicles and
exosomes are intercellular protein and RNA transporters
and share other functions that are discussed in this
review.
Other cellular vesicles include argosomes, blebs, and
apoptotic bodies. Argosomes are exosome-like vesicles
that contain morphogens, proteins that form a concentra-
tion gradient in the tissue, which is involved in signal
transduction to convey cellular position during develop-
ment in multicellular organisms. Argosomes differ from
exosomes mainly in their function. They were found to be
released from the basolateral membrane of wing disc cells
of Drosophila melanogaster. The spread of their morpho-
gens through epithelium promotes development (2,3). It
is suggested that they are involved in the direct transfer
of materials between donor and recipient cells. Until
recently, no standardized method of isolation or any
specific marker for these extracellular vesicles was
developed.
Apoptotic blebs are protrusive blisters formed when
cellular plasma membrane delaminates from the cortical
cytoskeleton, covering the entire surface of apoptotic
cells. The formation of apoptotic blebs is a physical
process that results from an increase in hydrostatic
pressure following cellular contraction (4). This dynamic
cyclic process of bleb formation and retraction can occur
over sustained periods during the progression of pro-
grammed cell death. Apoptotic blebs become packed with
cellular organelles and chromatin to form the basis of
fragmentary membrane-clad apoptotic bodies. Some in
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vitro studies have reported that inhibition of apoptotic
blebbing significantly impaired corpse clearance by
monocytes and macrophages (5,6). Apoptotic bodies
are the final consequences of cellular fragmentation.
They are 1000-5000 nm extracellular vesicles that contain
intact organelles, DNA, and histones (7). Apoptotic bodies
do not come under the scope of this review, but more
information about isolation and characteristics can be
found in Table 1, which summarizes the differences
between well-characterized extracellular vesicles, exo-
somes, microvesicles, and apoptotic bodies.
There is increasing interest in the study of the
importance and function of extracellular vesicles and this
review analyzes the mechanism of production and
function, and potential clinical uses of extracellular
vesicles in renal diseases.
Exosomes: formation and release
Exosomes are secreted by many cell types (8-10), and
have been isolated from several physiological fluids such
as sperm (11), urine (12), plasma (13), and bronchial
lavage fluid (14). They have a diameter of 40-100 nm, a
homogeneous shape, with a density of 1.13-1.19 g/mL in
sucrose, and can be sedimented at 100,000 g. Most
exosomes have an evolutionarily conserved set of
proteins, including tetraspanins, Alix, and Tsg101, and
have specific proteins that reflect their cellular source (1)
(Table 1). They are formed from multivesicular bodies
(MVBs), which are intracellular endosomal organelles,
characterized by multiple intraluminal vesicles enclosed
within a single outer membrane. MVBs are formed from
early endosomes, which as prelysosomal structures
belong to the degradative endosomal pathway of inter-
nalized proteins. They are now known to be involved in
numerous endocytic and trafficking functions, including
protein sorting, recycling, transport, storage, and release.
Actually, some authors recognize two types of MVBs, one
in the degradative pathway and another in the exocytosis
or recycling pathway (15).
Early endosomes can interact with the Golgi appara-
tus and the endoplasmic reticulum. Exosomes can be
formed by endocytosis of the early endosome membrane,
having a unique orientation of the involuted cytoplasmic
side (16,17) (Figure 1). Generation of MVBs as well as
secretion of exosomes are mediated through the con-
certed action of endosomal complexes required for
transport (ESCRT complexes). These protein complexes
are involved in the recognition of ubiquitinated cargo by
MVBs, as well as the invagination of the MVB outer
membrane (18,19).
The origin of exosomes suggests that their production
is stimulated in response to alterations in the microenvi-
ronment. The formation of early endosomes and MVBs
has been shown to increase upon signaling via growth
factor receptors, suggesting that the cell adjusts exosome
production according to its need (12,20).
Table 1. Main differences between extracellular vesicles, in vitro isolation methods, cargo, size, and function.
Exosome Microvesicle, ectosome,
shedding vesicles
Apoptotic bodies
Size 40-100 nm 100-1000 nm 1000-5000 nm
Markers CD63, CD9, Alix, TSG 101, HSP 70 Anexin V, Flotillin-2, selectin,
integrin, CD40 metalloproteinase
Anexin V, DNA, histones
Isolation method Immunoprecipitation (ExoQuick1),
ultracentrifugation (100,000-200,000 g),
ultracentrifugation with density gradient
Ultracentrifugation
(10,000-60,000 g)
No standardized protocol
References 49,53 54 55
Figure 1. Early endosomes (EE) are formed by endocytosis
following microenvironment modifications. The EE undergo
maturation forming the late endosome or multivesicular body
(MVB). During this process, EE communicate with the Golgi
apparatus through bidirectional vesicle exchange. Inward bud-
ding of the membrane forms the intraluminal vesicles that will be
released to the extracellular space as exosomes, or will fuse with
lysosomes where an active degradation process will take place.
Extracellular vesicles and potential uses in kidney diseases 825
www.bjournal.com.br Braz J Med Biol Res 46(10) 2013
Microvesicles: formation, release, and main
characteristics
Microvesicles are extracellular vesicles ranging in size
from 100-1000 nm, with different shapes. Although some
authors use the term microvesicles for extracellular
vesicles in general, the main differences between
exosomes and microvesicles depend on size, formation,
and the secretion process. They are formed by regulated
release of outward budding of the plasma membrane.
Several authors use different markers for microvesicles
like flotillin-2, selectins, integrins, metalloproteinases, and
a high level of phosphatidylserine on the outer surface
(Table 1). These extracellular vesicles can be isolated by
ultracentrifugation (21), and it is not known if overlapping
can occur between these two different populations of
extracellular vesicles. There are some resemblances
between them: both carry proteins, mRNA, and
microRNA (miRNA) and are involved in cellular commu-
nication (22,23), possibly through the horizontal transfer
of genetic material, directly stimulating the target cell by
transferring receptors or proteins.
Extracellular vesicle functions
Cellular communication
Exosomes could be a vehicle by which cells commu-
nicate with each other. This finding is supported by
experiments where exosomes modulated the function of
specific cell lines but not others (24). In addition,
exosomes produced by one type of cell can stimulate
another specific cell line. For example, exosomes from
human bone marrow mesenchymal stem cells can
stimulate proximal tubular cells to proliferate through the
transfer of hepatocyte growth factor-1 receptor mRNA,
suggesting the horizontal transfer of genetic material (25).
Exosomes mediate communication between neigh-
boring cells through a paracrine mechanism and also
through long-distance targeting via the systemic circula-
tion similar to hormones (i.e., an endocrine mechanism).
This observation is supported by the fact that exosomes
have been obtained from various biological fluids such as
urine, blood, and breast milk (26). In addition, exosomes
extracted from mesenchymal stem cells in culture were
administered systemically to animals and protected them
against acute kidney injury (AKI), induced ischemia/
reperfusion (I/R) (27), and nephrotoxic antibiotics (28).
It was observed that about 60% of the proteins carried
by these vesicles were obtained from exosomes of
different cell lines (intestinal epithelial cells, T cells, B
cells), suggesting that some proteins were constitutively
present in these structures to mediate its functions (29).
But also the presence of exosome proteins that were not
present in the cytoplasm of the donor cell was observed,
indicating that they were produced specifically for the
mechanism of exosome-mediated communication or
other functions (29).
Exosomes carry bioactive lipids like phospholipases
A2, C and D, and prostaglandins that may be involved in
the clearance of exosomes (30). Interestingly, no DNA
has been found in exosomes, and the RNA they contain
does not exactly reflect the quantity of miRNA and RNA in
the cells where they originated.
Supporting the communication function, exosomes not
only have the capacity to carry a large cargo load, but
can protect the contents from degradative enzymes like
RNase, trypsin, or chemical substances, due to its bi-lipid
membrane (31,32).
The recipient cell can take up this extracellular vesicle
through different mechanisms. Exosomes carry mem-
brane proteins that have binding affinity to ligands on the
recipient cell membranes or the extracellular matrix, such
as transferrin receptor, tumor necrosis factor receptors,
lactadherins, integrins, and tetraspanin proteins (e.g.,
CD9, CD63, and CD81) (33). These membrane molecules
may be involved in the homing of exosomes to a specific
tissue or microenvironment (15).
Another mechanism of uptake involves fusion with
recipient cell membrane, resulting in transfer of the
contents of exosomes (mRNAs, miRNAs, proteins, and
signaling molecules) or endocytosis (34-36). The
mechanism by which these processes are regulated
remains to be understood, but it is observed that exosome
uptake correlated with intracellular and microenvironmen-
tal acidity (37).
Additionally, it was observed that the RNA carried by
exosomes was taken up and translated in the recipient
cell, demonstrating that they carry functional RNA (24).
The findings support the hypothesis that exosomes can
be secreted by a specific stimulus, transported to the
recipient cell and taken up, and can stimulate the recipient
cell.
Microvesicles formed by budding from the plasma
membrane are also involved in intercellular communica-
tion. The main communication mechanism characterized
in the kidney is mediated by microvesicles released from
mesenchymal stem cells that reprogram injured kidney
cells (38). But both of the extracellular vesicles, i.e.,
exosomes and microvesicles, share some characteristics
such as the capability to reprogram the recipient cell.
Extracellular vesicles and kidney diseases
There are several functions suggested for the exo-
somes in kidney diseases. They may mediate the transfer
of information during renal tubule hypertrophy after
nephron loss. Enlargement of renal tubule cells, widening
of the tubule lumen followed by an increase in single-
nephron glomerular filtration rate, and the transport
capacity for salt and water can be mediated by exosome
signaling in downstream nephron segments (39).
Proximal tubular cell proteins found in downstream
segments of the nephron (collector ducts) were probably
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transported by exosomes, demonstrating the communica-
tion function. The protein or RNA content in exosomes
can reflect the cellular origin of the extracellular vesicle,
and alteration in the microenvironment indicates an early
phase of injury (40), emphasizing the diagnostic potential
of extracellular vesicles in kidney diseases.
A number of studies have reported the regenerative
potential of microvesicles derived from mesenchymal or
endothelial progenitor stem cells against acute kidney
injury induced by glycerol (38), cysplatin (41), ischemia,
and reperfusion (27) in animals. It was reported that
exosomes from mesenchymal stem cells protected rats
against nephrotoxic drugs like gentamicin (28).
Extracellular vesicles are involved in the pathophysio-
logical development of diseases. We observed that
exosomes from hypoxic proximal cells carrying tumor
growth factor-b mRNA could activate fibroblasts to
proliferate and produce matrix proteins as another early
mechanism of early fibroblast activation during fibrosis
(20). Microvesicles also have an important function in the
progression of diseases. The human renal carcinoma
cells expressing CD105 release microvesicles that stimu-
late neoangiogenesis. This may be implicated in tumor
progression, and in formation of a premetastatic niche in
the lung (42). So extracellular vesicles are implicated in
both the disease process and regeneration.
Extracellular vesicles as potential biomolecules in
diagnostic tools
The potential of exosomes as diagnostic molecules is
highly promising. Proteasome analysis of urinary exo-
somes has identified proteins from all segments of the
nephron, including glomerular podocytes (podocin and
podocalyxin), proximal tubules (megalin, cubilin, aqua-
porin-1, and type IV carbonic anhydrase), thick ascending
limb of Henle (type 2 Na-K-2Cl cotransporter), distal
convoluted tubule (thiazide-sensitive Na-Cl cotranspor-
ter), and the collecting duct (aquaporin 2) (12). They have
been shown to reflect acute kidney injury and are
candidate diagnostic markers (43). In another study, the
excretion of exosomes containing aquaporin-1 protein
was decreased in rats subjected to I/R (up to 96 h) but
later returned to normal levels (after 480 h). The same
result was observed in patients after renal allograft
transplantation, suggesting that aquaporin-1 carried by
exosomes in urine may allow early-to-late detection of
renal cellular states after I/R-induced injury and the
subsequent regeneration. So extracellular vesicles may
be used to predict post-transplant AKI (delayed graft
failure) (44).
In healthy humans, urinary exosome analysis has
identified over 1000 proteins from different segments of
the nephron, but, most importantly, 34 of them were
implicated in many kidney diseases such as autosomal
dominant polycystic kidney disease type 1 (polycystin-1),
autosomal dominant and recessive nephrogenic diabetes
(aquaporin-2), antenatal Bartter syndrome type 1 (Na-K-
2Cl symport), and Gitelman’s syndrome (thiazide-sensitive
Na-Cl cotransporter) (45). Nevertheless, additional studies
are necessary to analyze these proteins in exosomes from
patients with these diseases (12,45,46).
It was observed that circulating miRNA is decreased in
patients with chronic kidney disease and is correlated with
the decrease in estimated glomerular filtration rate. The
authors suggest that total and specific miRNA can be
used as biomarkers of uremia (47).
As observed for exosomes, microvesicles have been
investigated for potential use as diagnostic tools. In
tumors, microvesicles could be used to determine the
status of the tumor and mRNA could indicate the origin of
the microvesicle (48).
Exosomes as a drug delivery system
More recently, the property of exosomes as vehicles
for intercellular communication has been exploited for the
delivery of therapeutic small interfering RNAs (siRNAs)
to the brain and to provide alternative routes for drug
delivery systems, much as a ‘Trojan Horse’ (49). Through
this strategy, the HIV retrovirus exploits the machinery of
exosome genesis for intercellular communication in the
host cell to perform virus assembly and the cellular spread
of infection in the host, independently of the binding of
virus envelope protein to the cell receptor (50).
Development of such a delivery system for therapeutic
purposes faces many challenges, including ethical and
technical issues; for example, choice of the best gene
transfection method to introduce the RNA/protein of
interest (cargo) into exosome-secreting cells (virus,
lipofection, electroporation), how to target the cargo into
the exosomes, the best technique to load exosomes with
the drug of interest (electroporation or lipofection), and the
cost of the process are a few of the concerns that need to
be addressed.
On the contrary, exosomes have many unique
attributes that make them an excellent choice as a drug
delivery system: both protein and genetic material can be
loaded into exosomes, they are well tolerated by the
human body, have a long circulating half-life, are capable
of membrane penetration, have intrinsic homing ability,
and are amenable to membrane modifications (51). If we
consider mesenchymal stem cell exosomes and micro-
vesicles, the therapeutic potential improves. Since they
are easily accessible in vitro, mesenchymal stem cells
have a large capacity for expansion, are nonimmuno-
genic, and have the intrinsic therapeutic property of
reducing tissue injury, as highlighted by different authors
(27,28,38,41,52).
Although research on the use of microvesicles/
exosomes for drug delivery in kidney diseases is still in
its infancy, one study analyzed the potential of chemically
modified 143 miR transfected in THP-1 macrophages ex
vivo, and microvesicles were isolated and injected into
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xenografted nude animals. The microvesicles were
localized in serum, tumor, and kidney of the host animal.
These experiments indicate that the cargo of microvesi-
cles can be modified to deliver miRNA, and probably
mRNA and proteins, to the kidney of the host (52).
Although this mechanism has an important therapeutic
potential, more studies are still necessary to sufficiently
address a number of issues related to safety and ethics.
Conclusion and future directions
The use of exosomes as diagnostic biomolecules in a
wide range of diseases and as a therapeutic drug delivery
system is highly promising. Nevertheless, more studies
are required to understand the mechanism of exosome
formation and release as well as their physiological and
pathological functions in different organs and systems,
including non-cancer-related kidney diseases.
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